<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03233139</url>
  </required_header>
  <id_info>
    <org_study_id>R2810-ONC-1622</org_study_id>
    <nct_id>NCT03233139</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of REGN2810 (Cemiplimab) (Anti-PD-1) in Japanese Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase 1 Study to Investigate the Safety and Pharmacokinetics of REGN2810 (Anti-PD-1) in Japanese Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the safety, tolerability, and&#xD;
      Pharmacokinetics (PK) of cemiplimab in Japanese patients with advanced malignancies.&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
        -  To assess the immunogenicity of cemiplimab&#xD;
&#xD;
        -  To evaluate tumor response (objective response rate [ORR] and duration of response [DOR]&#xD;
           to cemiplimab monotherapy as first line treatment of Japanese patients with advanced&#xD;
           squamous or non-squamous non-small cell lung cancer (NSCLC) (Part 2, cohort A)&#xD;
&#xD;
        -  To evaluate tumor response ORR and DOR to cemiplimab plus chemotherapy as first line&#xD;
           treatment of Japanese patients with advanced squamous or non-squamous NSCLC (Part 2,&#xD;
           cohort C)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2017</start_date>
  <completion_date type="Anticipated">May 24, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 24, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs) in patients treated with cemiplimab</measure>
    <time_frame>Up to 136 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of cemiplimab: Cmax</measure>
    <time_frame>Up to 136 weeks</time_frame>
    <description>Peak serum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of cemiplimab: tmax</measure>
    <time_frame>Up to 136 weeks</time_frame>
    <description>Time to Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of cemiplimab: Ctrough</measure>
    <time_frame>Up to 136 weeks</time_frame>
    <description>Drug concentration in serum at the end of a dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of cemiplimab: Area under the drug concentration-time curve in serum AUC3w</measure>
    <time_frame>Up to 136 weeks</time_frame>
    <description>AUC over a 3-week dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of cemiplimab: t½ estimated over a 3-week dosing interval</measure>
    <time_frame>Up to 136 weeks</time_frame>
    <description>Observed terminal half-life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity against cemiplimab</measure>
    <time_frame>Up to 136 weeks</time_frame>
    <description>Evaluate the immunogenicity of cemiplimab after single-dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 135 weeks</time_frame>
    <description>As assessed by an Independent Review Committee (IRC) using RECIST 1.1 (Eisenhauer 2009) in Part 2, Cohorts A and C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 136 weeks</time_frame>
    <description>As assessed by an IRC (per RECIST1.1) in Part 2, Cohorts A and C</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>Cemiplimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cemiplimab</intervention_name>
    <description>Patients will be administered cemiplimab as per protocol</description>
    <arm_group_label>Cemiplimab</arm_group_label>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <other_name>REGN2810</other_name>
    <other_name>Libtayo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>To be administered per protocol</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platinum-doublet chemotherapy</intervention_name>
    <description>To be administered per protocol</description>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Disease types under study:&#xD;
&#xD;
               -  Part 1: Histologically or cytologically confirmed diagnosis of malignancy with no&#xD;
                  alternative standard-of-care therapeutic option&#xD;
&#xD;
               -  Part 2: Patients with histologically or cytologically documented squamous or&#xD;
                  non-squamous NSCLC with stage IIIB or IIIC or stage IV disease who received no&#xD;
                  prior systemic treatment for recurrent or metastatic NSCLC.&#xD;
&#xD;
               -  Patients in Part 2 NSCLC cohorts must have available archival or newly obtained&#xD;
                  formalin-fixed tumor tissue from a metastatic/recurrent site, which has not&#xD;
                  previously been irradiated.&#xD;
&#xD;
          2. ECOG (Eastern Cooperative Oncology Group) PS (Performance status) ≤1 (Restricted in&#xD;
             physically strenuous activity but ambulatory and able to carry out work of a light or&#xD;
             sedentary nature [eg, light house work or office work]). Note: Patients with ECOG PS&#xD;
             &gt;1 are ineligible.&#xD;
&#xD;
          3. Patients must have been born in Japan, and their biological parents and grandparents&#xD;
             must all have been of Japanese origin&#xD;
&#xD;
          4. Willing and able to comply with clinic visits and study-related procedures&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that&#xD;
             requires treatment with systemic immunosuppressive treatments, which may suggest risk&#xD;
             for Immune-related adverse event (irAE)s. The following are not exclusionary:&#xD;
             vitiligo, childhood asthma that has resolved, residual hypothyroidism that requires&#xD;
             only hormone replacement or psoriasis that does not require systemic treatment.&#xD;
&#xD;
          2. Untreated brain metastasis (es) that may be considered active. Patients with&#xD;
             previously treated brain metastases may participate provided they are stable, there is&#xD;
             no evidence of new or enlarging brain metastases, and the patient does not require any&#xD;
             systemic corticosteroids for management of brain metastases within 4 weeks prior to&#xD;
             the first dose of cemiplimab.&#xD;
&#xD;
          3. Immunosuppressive corticosteroid doses (&gt;10 mg prednisone daily or equivalent) within&#xD;
             4 weeks prior to the first dose of cemiplimab.&#xD;
&#xD;
          4. Any positive test (ribonucleic acid (RNA) or Deoxyribonucleic acid (DNA) by polymerase&#xD;
             chain reaction) for hepatitis B, hepatitis C, or human immunodeficiency virus&#xD;
             indicating uncontrolled active or chronic infection.&#xD;
&#xD;
          5. History of pneumonitis or interstitial lung disease&#xD;
&#xD;
          6. Surgery within 1 month of first dose and radiation therapy within 2 weeks of first&#xD;
             dose&#xD;
&#xD;
          7. Completed palliative radiation therapy within the prior 2 weeks or has not recovered&#xD;
             from any medically significant radiation-related Adverse Event (AE)&#xD;
&#xD;
          8. Patients that have never smoked, defined as smoking ≤100 cigarettes in a lifetime&#xD;
             (Part 2)&#xD;
&#xD;
          9. Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene&#xD;
             mutations, anaplastic lymphoma kinase (ALK) gene translocations, or ROS1 fusions (Part&#xD;
             2)&#xD;
&#xD;
        Note: Other protocol defined inclusion/exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nagoya Medical Center</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanazawa University Hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kitasato University Hospital</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cardiovascular and Respiratory Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sasebo City General Hospital</name>
      <address>
        <city>Sasebo</city>
        <state>Nagasaki</state>
        <zip>857-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>710-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hospital</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinki-Chuo Chest Medical Center</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka Medical College Hospital</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center</name>
      <address>
        <city>Kita Adachi</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Cho-Ku</city>
        <state>Tokyo</state>
        <zip>104-0055</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gunma Prefectural Cancer Center</name>
      <address>
        <city>Gunma</city>
        <zip>373-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Hiroshima Citizens Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Center</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokushima University Hospital</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 25, 2017</study_first_submitted>
  <study_first_submitted_qc>July 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2017</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

